Table 1.
Characteristics of the breast cancer patients with positive SLNs and univariate analysis of NSLN metastases
| Variable | Total | Negative | Positive | P |
|---|---|---|---|---|
| (n = 171) | NSLN (n = 115) | NSLN (n = 56) | ||
| Age | 0.639 | |||
| ≤50 years | 99 | 68 | 31 | |
| >50 years | 72 | 47 | 25 | |
| Tumor size | 0.022 | |||
| T1 | 112 | 81 | 30 | |
| T2 | 55 | 31 | 25 | |
| NA | 4 | 3 | 1 | |
| Histological grade | 0.134 | |||
| I | 37 | 29 | 8 | |
| II | 108 | 71 | 37 | |
| III | 24 | 13 | 11 | |
| NA | 2 | 2 | 0 | |
| SLNs | 0.935 | |||
| 1 | 53 | 37 | 16 | |
| 2 | 70 | 46 | 24 | |
| 3 | 31 | 20 | 11 | |
| ≥4 | 17 | 12 | 5 | |
| Positive SLNs | 0.000 | |||
| 1 | 137 | 101 | 36 | |
| ≥2 | 34 | 14 | 20 | |
| Ratio of positive SLN | 0.034 | |||
| ≤50% | 87 | 65 | 22 | |
| >50% | 84 | 50 | 34 | |
| Molecular subtype | 0.425 | |||
| Luminal A | 73 | 44 | 29 | |
| Luminal B | 64 | 45 | 19 | |
| HER2 overexpression | 11 | 9 | 2 | |
| Triple negative | 11 | 8 | 3 | |
| NA | 12 | 9 | 3 |
NA, not available; SLN, sentinel lymph node; HER2, human epidermal growth factor receptor 2; NSLN, non-SLN.